Advances in the surgical management of ovarian cancer

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 50, Issue 6, 2005, Pages 454-466

  Horowitz, Neil S ^a   Duska, Linda R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Gynecologic surgery; Local neoplasm recurrence; Ovarian cancer

Indexed keywords

ARGON PLASMA COAGULATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; GYNECOLOGIC CANCER; HUMAN; LAPAROSCOPY; OVARIECTOMY; OVARY CANCER; PELVIS EXENTERATION; PRIORITY JOURNAL; SPLENECTOMY; SURGEON; UNITED STATES;

CLINICAL COMPETENCE; DISEASE-FREE SURVIVAL; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; LAPAROSCOPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 20844433720     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (86)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26
2. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, et al: Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003; 189:1120-1127
3. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-104
4. Hacker NF, Berek JS, Lagasse LD, et al: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-420
5. Hacker NF, van der Burg M: Debulking and intervention surgery. Ann Oncol 1993;4:S17-S22
6. Delgado G, Oram D, Petrilli B: Stage III epithelial ovarian cancer: The role of maximal surgical reduction. Gynecol Oncol 1984;18:293-298
7. Hoskins WJ, McGuire W, Brady M, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994; 170:974-980
8. Makar A, Baekelandt M, Trope C, et al: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175-180
9. Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 1998;69:103-108
10. Vergote I, De Wever I, Decloedt J, et al: Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol (suppl 3) 2000;27:31-36
11. Brooks S, Ahn J, Mullins C, et al: Resources and use of the intensive care unit in patients who undergo surgery for ovarian carcinoma. Cancer 2002;95:1457-1462
12. Amir M, Shabot M, Karlan BY: Surgical intensive care unit care after ovarian cancer surgery: Analysis of indications. Am J Obstet Gynecol 1997;176:1389-1393
13. Kapnick SJ, Griffiths CT, Finkler NJ: Occult pleural involvement in stage III ovarian carcinoma: role of diaphragm resection. Gynecol Oncol 1990;39:135-138
14. Montz FJ, Schlaerth JB, Berek JS: Resection of diaphragmatic peritoneum and muscle: Role in cytoreductive surgery for ovarian cancer. Gynecol Oncol 1989;35:338-340
15. Bristow RE, del Carmen MG, Kaufman HS, et al: Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 2003;197:565-574
16. Eisenkop SM, Nalick RH, Teng NN: Modified posterior exenteration for ovarian cancer. Obstet Gynecol 1991;78:879-885
17. Gillette-Cloven N, Burger RA, Monk BJ, et al: Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg 2001;193:626-632
18. Morris M, Gershenson DM, Burke TW, et al: Splenectomy in gynecologic oncology: Indications, complications and technique. Gynecol Oncol 1991;43:118-122
19. Chen L-M, Leuchter RS, Lagasse LD, et al: Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 2000;77:362-368
20. Bristow RE, Montz FJ: Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 2001;83:39-48
21. Bristow RE, Sehdev Smith A, Kaufman HS, et al: Ablation of metastatic ovarian carcinoma with the argon beam coagulator: Pathologic analysis of tumor destruction. Gynecol Oncol 2001;83:49-55
22. Eisenkop SM, Nalick RH, Wang HJ, et al: Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: Impact on survival. Gynecol Oncol 1993;51:224-229
23. Flamm ES, Ransohoff J, Wuchinich D, et al: Preliminary experience with ultrasonic aspiration in neurosurgery. Neurosurgery 1978;2:240-245
24. Hodgson WJB, Poddar PK, Mencer EJ, et al: Evaluation of ultrasound powered instruments in the laboratory and in the clinical setting. Am J Gastroenterol 1979;72:133-140
25. Hodgson WJB, Sanjivani B, Harrington E, et al: General surgical evaluation of a powered device operating at ultrasonic frequencies. Mount Sinai J Med 1979;46:99-103
26. Hodgson WJB: The ultrasonic scalpel. Bull N Y Acad Med 1979;55:908-915
27. Little JM, Holland MJ: Impact of the CUSA and operative ultrasound on hepatic resection. Hepat Pancreat Bil Surg 1991;3:271-277
28. Fasulo F, Giori A, Fissi S, et al: Cavitron ultrasonic surgical aspirator (CUSA) in liver resection. Int Surg 1992;77:64-66
29. Horowitz N, Rader JS: Role of the ultrasonic surgical aspirator in gynecology and obstetrics. Gynecol Clin North Am 2001;28:775-790
30. Adelson MD: Cytoreduction of diaphragmatic metastases using the cavitron ultrasonic surgical aspirator. Gynecol Oncol 1991;41:220-222
31. Adelson MD, Baggish MS, Cassell SL, et al: Cytoreduction of ovarian cancer with the cavitron ultrasonic surgical aspirator. Obstet Gynecol 1988;72:140-143
32. Deppe G, Malviya V, Malone J: Debulking surgery for ovarian cancer with the cavitron ultrasonic surgical aspirator (CUSA): A preliminary report. Gynecol Oncol 1986;31:223-226
33. Adelson MD: Ultrasonic surgical aspirator in cytoreduction of splenic metastases to avoid splenectomy. J Reprod Med 1992;37:917-920
34. Patsner B, Rose PG: CUSA splenorrhaphy for ovarian cytoreductive surgery. Gynecol Oncol 1991;41:28-29
35. van Dam P, Tjalma W, Weyler J, et al: Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: A prospective randomized trial. Am J Obstet Gynecol 1996;174:943-950
36. Donovan JT, Veronikis DK, Powell JL, et al: Cytoreductive surgery for ovarian cancer with the cavitron ultrasonic surgical aspirator and development of disseminated intravascular coagulation. Obstet Gynecol 1994;83:1011-1014
37. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11:166-172
38. Bristow RE, Duska LR, Lambrou NC, et al: A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89: 1532-1540
39. Saygili U, Guclu S, Uslu T, et al: Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 2002;86:57-61
40. Chi DS, Venkatraman ES, Masson V, et al: The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:227-231
41. Vrscaj MU, Rakar S: Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: A retrospective case-control study. Eur J Gynaecol Oncol 2002;23:405-410
42. Vergote I, De Wever I, Tjalma W, et al: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-436
43. Zylberberg B, Dormont D, Janklewicz S, et al: Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol 2001;22:40-45
44. van der Burg M, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer: Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332: 629-634
45. Rose PG, Nerenstone S, Brady M, et al: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351:2489-2497
46. Bonnefoi H, Ahern RP, Fisher C, et al: Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:767-775
47. Jacob JH, Gershenson DM, Morris M, et al: Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-150
48. Potter ME, Partridge EE, Hatch KD, et al: Primary surgical therapy of ovarian cancer: How much and when. Gynecol Oncol 1991;40:195-200
49. Naik R, Nordin A, Cross PA, et al: Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 2000;78:171-175
50. Curtin JP, Malik R, Venkatraman ES, et al: Stage IV ovarian cancer: Impact of surgical debulking. 1997;64:9-12
51. Liu PC, Benjamin I, Morgan MA, et al: Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997;64:4-8
52. Bristow RE, Montz FJ, Lagasse LD, et al: Survival impact of surgical cytoreduction in stage iv epithelial ovarian cancer. Gynecol Oncol 1999;72:278-287
53. Munkarah AR, Hallum AV 3rd, Morris M, et al: Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-17
54. Eisenkop SM, Friedman RL, Spirtos NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000;88:144-153
55. Eisenkop SM, Friedman RL, Wang HJ: Secondary cytoreductive surgery for recurrent ovarian cancer: A prospective study. Cancer 1995;76:1606-1614
56. Zang RY, Zhang ZY, Li ZT, et al: Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur J Surg Oncol 2000;26:798-804
57. Janicke F, Holscher M, Kuhn W, et al: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129-2136
58. Vaccarello L, Rubin SC, Vlamis V, et al: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995;57: 61-65
59. Gadducci A, Iacconi P, Cosio S, et al: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000;79: 344-349
60. Segna RA, Dottino PR, Mandeli JP, et al: Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993;11:434-439
61. Tay E-H, Grant PT, Gebski V, et al: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002;99:1008-1013
62. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21: 3194-3200
63. Chu C, Rubin SC: Second-look laparotomy for epithelial ovarian cancer: A reappraisal. Curr Oncol Rep 2001;3:11-18
64. Querleu D, LeBlanc E, Castelain B: Laparoscopic pelvic lymphadenectomy in the staging of early carcinoma of the cervix. Am J Obstet Gynecol 1991;164:579-581
65. Scribner DR, Walker JL, Johnson GA, et al: Laparoscopic pelvic and paraaortic lymph node dissection: Analysis of the first 100 cases. Gynecol Oncol 2001;82:498-503
66. Querleu D, Papageorgiou T, Lambaudie E, et al: Laparoscopic restaging of borderline ovarian tumors: Results of 30 cases initially presumed as stage IA borderline ovarian tumours. Br J Obstet Gynaecol 2003;110:201-204
67. Leminem A, Lehtovirta P: Spread of ovarian cancer after laparoscopic surgery: Report of eight cases. Gynecol Oncol 1999;75:387-390
68. Hopkins MP, von Gruenigen V, Gaich S: Laparoscopic port site implantation with ovarian cancer. Am J Obstet Gynecol 2000;182:735-736
69. Husain A, Chi DS, Prasad M, et al: The role of laparoscopy in second-look evaluations for ovarian cancer. Gynecol Oncol 2001;80:44-47
70. Clough KB, Ladonne JM, Nos C, et al: Second-look for ovarian cancer: Laparoscopy or laparotomy? A prospective comparative study. Gynecol Oncol 1999;72:411-417
71. Casey AC, Farias-Eisner R, Pisani AL, et al: What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995? Gynecol Oncol 1996;60:454-461
72. Einat S, Amir S, Silvia M, et al: Successful laparoscopic removal of a solitary adrenal metastasis from ovarian carcinoma: A case report. Gynecol Oncol 2002;85:201-203
73. Cass I, Li A, Runowicz C, et al: Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001;80:56-61
74. Duska LR, Chang Y, Flynn C, et al: Epithelial ovarian cancer in the reproductive age group. Cancer 1999;85:2623-2629
75. Plaxe S, Braly P, Freddo J, et al: Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol 1993;81:651-654
76. Chan JK, Lin YG, Loizzi V, et al: Borderline ovarian tumors in reproductive-age women: Fertility sparing surgery and outcome. J Reprod Med 2003;48:756-760
77. Schilder JM, Thompson AM, DePriest PD, et al: Outcome of reproductive age women with stage Ia or Ic invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002;87:1-7
78. Zanetta G, Chiari S, Rota S, et al: Conservative surgery for stage I ovarian carcinoma in women of childbearing age. Br J Obstet Gynaecol 1997;104:1030-1035
79. Morice P, Wicart-Poque F, Key A, et al: Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001; 92:2412-2418
80. Elit L, Bondy SJ, Paszat L, et al: Outcomes in surgery for ovarian cancer. Gynecol Oncol 2002;87:260-267
81. Woodman C, Baghdady A, Collins S, et al: What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer? Br J Obstet Gynaecol 1997;104:135-139
82. Sengupta PS, Jayson GC, Slade RJ, et al: An audit of primary surgical treatment for women with ovarian cancer referred to a cancer centre. Br J Cancer 1999;80:444-447
83. Junor EJ, Hole DJ, McNulty L, et al: Specialist gynaecologists and survival outcome in ovarian cancer: A Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999;106:1130-1136
84. Eisenkop SM, Spirtos NM, Montag TW, et al: The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-209
85. Pule LE, Carrasco R, Morrow MS, et al: Stage I ovarian carcinoma: Specialty-related differences in survival and management. South Med J 1997;90:1097-1100
86. Carney ME, Lancaster JM, Ford C, et al: A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 2001;84:36-42